Letrozol Medical Valley (Letrozole)

Letrozole blocks the aromatase enzyme, which converts adrenal and ovarian androgens into estrogen. By inhibiting this conversion, systemic estrogen production drops, reducing the hormonal stimulus that drives the growth of certain breast cancers.

The dosage of letrozole is determined by the prescribing physician based on the patient’s clinical condition, treatment setting and regulatory guidelines. Patients should follow the exact regimen provided by their healthcare professional.

Letrozole is classified as pregnancy category X, meaning it is contraindicated during pregnancy because it can harm the fetus. It is also not recommended for breastfeeding mothers, as it may be excreted in breast milk and affect the infant.

To order Letrozol Medical Valley, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrozole, anastrozole and exemestane are the three main aromatase inhibitors. Letrozole is a non‑steroidal, highly selective inhibitor with a long half‑life, often chosen for its potency in reducing estrogen levels. Choice among them depends on patient tolerance, prior therapy and physician preference.

Letrozol Medical Valley should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain its stability.

The medication is taken orally, usually as a tablet swallowed with water. Patients should follow the dosing schedule prescribed by their healthcare provider and take the drug consistently each day to maintain steady drug levels.

Serious risks include severe liver injury, osteoporosis‑related fractures, deep‑vein thrombosis or pulmonary embolism, and rare allergic reactions such as anaphylaxis. Patients should be monitored regularly for signs of these conditions and report any concerning symptoms promptly.

Letrozole should not be used by pregnant or breastfeeding women, premenopausal patients, individuals with known hypersensitivity to letrozole or other aromatase inhibitors, and patients with severe liver impairment without appropriate medical supervision.